How should the SLED prescription be adjusted for a patient with persistently elevated BUN and creatinine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 5, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

SLED Prescription Adjustment for Persistently Elevated BUN and Creatinine

Increase the SLED treatment duration toward 12 hours and/or increase the frequency of sessions to achieve adequate solute clearance, targeting a delivered Kt/V of at least 1.2-1.4 per treatment, while maintaining hemodynamic stability. 1

Treatment Duration and Frequency Optimization

  • Extend treatment sessions to the full 12-hour duration when BUN and creatinine remain elevated, as the mean delivered double-pool Kt/V of 1.36 per completed treatment in SLED requires adequate time to achieve target clearance 1

  • Consider increasing treatment frequency from every other day to daily sessions if solute control remains inadequate with standard scheduling, as SLED allows for flexible scheduling while maintaining hemodynamic stability 1

  • Monitor delivered versus prescribed dose closely, as interruptions for circuit clotting, procedures, or hypotension can reduce actual delivered clearance by 15-32% below prescribed targets 2

Blood and Dialysate Flow Rate Adjustments

  • Maintain the standard SLED approach of reduced blood flow rates (typically 200-300 mL/min) and low dialysate flow rates (typically 100-300 mL/min) to preserve hemodynamic stability, which is the primary advantage of SLED over conventional intermittent hemodialysis 1

  • Do not increase flow rates aggressively in pursuit of higher clearance, as this defeats the hemodynamic stability advantage and may lead to treatment intolerance and premature discontinuation 1

Clearance Target Monitoring

  • Aim for urea-based clearance targets extrapolated from maintenance hemodialysis (Kt/V ≥1.2 per treatment for SLED), recognizing these are borrowed metrics in the absence of AKI-specific adequacy measures 2

  • Perform direct dialysis quantification when possible to verify delivered dose, as prescribed clearance can overestimate actual delivered clearance by up to 25% due to filter efficiency decline and treatment interruptions 2

Common Pitfalls and Monitoring

  • Anticipate and prevent circuit clotting, which was the majority cause of premature SLED discontinuation in clinical experience, by optimizing anticoagulation protocols 1

  • Watch for electrolyte depletion, particularly hypophosphatemia and hypokalemia, which may require supplementation during extended SLED sessions (mean phosphate removal 1.5g per treatment) 1

  • Accept that some patients may require 20-25% higher prescribed flow rates than target doses to account for downtime and filter efficiency decline, though this remains debated among experts 2

Hemodynamic Considerations

  • Prioritize hemodynamic stability over aggressive clearance, as SLED's primary indication is for patients in whom conventional intermittent hemodialysis has failed or been withheld due to hemodynamic instability 1

  • Achieve ultrafiltration goals gradually over the extended treatment time, as SLED maintained hemodynamic stability in most treatments with a mean ultrafiltration shortfall of only 240 mL per treatment 1

  • Schedule treatments nocturnally when feasible to allow unrestricted daytime access for procedures and tests while maintaining adequate clearance 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

What is the clinical significance of the BUN-to-creatinine ratio and how should abnormal values be evaluated and managed?
What explains a mildly low serum creatinine with normal BUN and a modestly elevated BUN‑to‑creatinine ratio, and what is the appropriate clinical approach?
What are the implications of a slightly elevated Blood Urea Nitrogen (BUN)/creatinine ratio with normal estimated Glomerular Filtration Rate (eGFR) and normal BUN and creatinine levels?
What is the significance of an elevated Blood Urea Nitrogen (BUN) level in the context of otherwise normal Basic Metabolic Panel (BMP) lab results?
What are the implications of an elevated BUN to creatinine ratio on kidney function?
Is a 30-year-old brain-dead donor after traumatic cranial injury with a pulmonary infection eligible for kidney donation?
In a patient with poorly controlled asthma on dupilumab (Dupixent) being evaluated for allergic bronchopulmonary aspergillosis who presents with an acute asthma exacerbation, should the dupilumab dose be administered today?
What is the recommended treatment plan for a 43‑year‑old hypermobile patient with a confirmed acetabular labrum tear, L5/S1 radiculopathy, and a prior complete long‑head biceps tendon tear?
For a patient at high altitude, will raising ferritin stores improve oxygen delivery?
Can inflammation from a vulvar Candida infection spread to the surrounding groin and buttock skin, causing a burning sensation?
Does Zyprexa (olanzapine) cause involuntary movements?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.